[A case of Pompe disease treated with acid alpha-glucosidase].
Katarzyna Kapica-Topczewska, Joanna Tarasiuk, Alina Kułakowska, Wiesław Drozdowski
Abstract
Katarzyna Kapica-Topczewska, Joanna Tarasiuk, Alina Kułakowska, Wiesław Drozdowski
Abstract
Pompe disease (type II glycogenosis--GSD II) is a progressive metabolic myopathy caused by lysosomal storage of glycogen due to deficiency of acid alpha-glucosidase. We present the case of a 32-year-old patient with Pompe disease diagnosed 14 years ago in whom enzyme replacement therapy with recombinant human acid alpha-glucosidase (rhGAA) (20 mg/kg i.v. every 2 weeks) has been administered for about 18 months. Despite the fact that therapy was started in the advanced phase of Pompe disease we observed clinical improvement (increased muscle bulk and muscle strength as well as increased range of movements in the distal parts of limbs). In addition, we noticed less effort dyspnoea and use of a respirator during the day shortened to 2-3 hours (previously 5 hours). According to the observation of our patient, we suggest that enzyme replacement therapy causes clinical improvement.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Pompe disease (type II glycogenosis--GSD II) is a progressive metabolic myopathy caused by lysosomal storage of glycogen due to deficiency of acid alpha-glucosidase. We present the case of a 32-year-old patient with Pompe disease diagnosed 14 years ago in whom enzyme replacement therapy with recombinant human acid alpha-glucosidase (rhGAA) (20 mg/kg i.v. every 2 weeks) has been administered for about 18 months. Despite the fact that therapy was started in the advanced phase of Pompe disease we observed clinical improvement (increased muscle bulk and muscle strength as well as increased range of movements in the distal parts of limbs). In addition, we noticed less effort dyspnoea and use of a respirator during the day shortened to 2-3 hours (previously 5 hours). According to the observation of our patient, we suggest that enzyme replacement therapy causes clinical improvement.
Key concepts: Medicine, Enzyme replacement therapy, Glycogen storage disease type II, Myopathy, Glycogen storage disease, Glycogen, Disease, Internal medicine